Core Viewpoint - Aojing Medical (688613.SH) forecasts a net profit attributable to shareholders of approximately 13.53 million yuan for the year 2025, representing an increase of about 26.19 million yuan compared to the previous year, indicating a turnaround from loss to profit [1] Group 1: Performance Forecast - The company expects to achieve a net profit of approximately 13.53 million yuan in 2025 [1] - This represents an increase of about 26.19 million yuan compared to the same period last year [1] - The anticipated performance marks a significant turnaround from previous losses [1] Group 2: Reasons for Performance Change - The main reason for the performance change is the increase in clinical usage of orthopedic artificial bone due to centralized procurement, which provides opportunities for continued market share expansion [1] - The company has strengthened its production assurance system to meet the increased demand resulting from centralized procurement [1] Group 3: Marketing and Sales Strategy - The company continues to deepen its regional market strategy through refined management and targeted marketing strategies [1] - There is a steady growth trend in annual operating revenue, further consolidating the company's leading position in the niche market [1]

Group 1 - The core viewpoint of the article is that Aojing Medical is expected to achieve a net profit of approximately 13.53 million yuan for the year 2025, marking an increase of about 26.19 million yuan compared to the previous year, thus turning a profit [1] - The main reason for the performance change is the opportunity provided by the centralized procurement of orthopedic artificial bones, which has allowed the company to increase clinical usage and further expand its market share [1] - The company has strengthened its production guarantee system to ensure stable supply to meet the increased demand from centralized procurement [1] Group 2 - In terms of marketing strategy, the company continues to deepen its regional market strategy through refined management and precise marketing tactics, thereby expanding its sales network [1] - The company's annual operating revenue shows a steady growth trend, further consolidating its leading position in the niche market [1]

Core Viewpoint - The company, AoJing Medical, is expected to achieve a net profit of approximately 13.53 million yuan for the fiscal year 2025, marking a turnaround from previous losses [1] - The projected revenue for 2025 is around 224 million yuan, reflecting a year-on-year growth of approximately 8.48% [1] Group 1 - The anticipated net profit indicates a significant improvement in the company's financial performance, moving from loss to profit [1] - The expected revenue growth is attributed to the increased clinical usage and market share expansion opportunities provided by the orthopedic artificial bone procurement [1]

Core Viewpoint - The company, AoJing Medical, forecasts a total revenue of 224 million yuan for the year 2025, driven by opportunities in the orthopedic artificial bone market and enhanced production capabilities [1] Group 1: Revenue and Profit Growth - For the first three quarters of 2025, the company's main revenue reached 156 million yuan, an increase of 5.22% year-on-year [1] - The net profit attributable to the parent company for the same period was 13.94 million yuan, reflecting a significant year-on-year increase of 185.19% [1] - The company's net profit after deducting non-recurring items was 3.10 million yuan, up 137.11% year-on-year [1] Group 2: Quarterly Performance - In the third quarter of 2025, the company's single-quarter main revenue was 56.02 million yuan, representing a year-on-year increase of 16.54% [1] - The net profit attributable to the parent company for the third quarter was 5.97 million yuan, showing a remarkable year-on-year increase of 237.64% [1] - The net profit after deducting non-recurring items for the third quarter was 3.11 million yuan, up 132.36% year-on-year [1] Group 3: Market Strategy and Financial Health - The company is enhancing its production assurance system to meet the increased demand from centralized procurement in the orthopedic market [1] - The marketing strategy focuses on deepening regional market strategies through refined management and targeted marketing, which helps to expand the sales network [1] - The company's debt ratio stands at 6.22%, with investment income of 39,800 yuan and financial expenses of 152.09 million yuan, while maintaining a gross profit margin of 68.9% [1]

市场营销策略方面，公司持续深化区域市场战略，通过精细化管理和精准营销策略，不断拓宽销售网 络。公司全年营业收入呈现稳健增长态势，进一步巩固了公司在细分市场的领先地位。 奥精医疗2025年三季报显示，前三季度公司主营收入1.56亿元，同比上升5.22%；归母净利润1394.06万 元，同比上升185.19%；扣非净利润310.45万元，同比上升137.11%；其中2025年第三季度，公司单季度 主营收入5602.1万元，同比上升16.54%；单季度归母净利润596.53万元，同比上升237.64%；单季度扣 非净利润310.63万元，同比上升132.36%；负债率6.22%，投资收益3.98万元，财务费用152.09万元，毛 利率68.9%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，奥精医疗发布业绩预告，预计2025年全年归属净利润盈利约1353.17万元。 公告中解释本次业绩变动的原因为： 骨科人工骨集采为公司提供了临床使用继续上量、进一步扩大市场份额的机会。以此为契机，公司同步 强化了生产保障体系，确保能稳定 ...

证券代码:688613 证券简称:奥精医疗 公告编号:2026-004 奥精医疗科技股份有限公司 1、预计2025年年度实现营业收入为22,350.56万元左右，与上年同期（法 定披露数据）相比，预计将增加1,747.26万元左右，同比增加8.48%左右。 2、预计2025年年度实现归属于母公司所有者的净利润为1,353.17万元左右， 与上年同期相比，预计将增加2,619.38万元左右，将实现扭亏为盈。 3、预计2025年年度实现归属于母公司所有者扣除非经常性损益后的净利润 为-51.47万元左右，与上年同期相比，预计将增加2,785.64万元左右。 （三）本次业绩预告未经注册会计师审计。 2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 经奥精医疗科技股份有限公司（以下简称"公司"）财务部门初步测算： 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务 所审计，公司尚未发现影响本次 ...

Core Viewpoint - The company, Aojing Medical (688613.SH), anticipates a significant increase in revenue and a turnaround in profitability for the year 2025, driven by strategic market initiatives and enhanced production capabilities [1] Financial Projections - The company expects to achieve an operating revenue of approximately 223.51 million yuan in 2025, representing an increase of about 17.47 million yuan or 8.48% compared to the previous year [1] - The projected net profit attributable to the parent company is around 13.53 million yuan, an increase of approximately 26.19 million yuan, indicating a turnaround from a loss to profitability [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, is expected to be around -514,700 yuan, reflecting an increase of approximately 2.78 million yuan compared to the previous year [1] Market Strategy and Growth - The orthopedic artificial bone procurement has provided the company with opportunities for continued clinical usage growth and market share expansion [1] - The company is enhancing its production assurance system to meet the increased demand resulting from the procurement [1] - The marketing strategy focuses on deepening regional market strategies through refined management and targeted marketing efforts, continuously expanding the sales network [1] - The company has demonstrated steady revenue growth throughout the year, further solidifying its leading position in the niche market [1]

南财智讯1月28日电，奥精医疗发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 1353.17万元左右，预计同比扭亏；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润 为-51.47万元左右。骨科人工骨集采为公司提供了临床使用继续上量、进一步扩大市场份额的机会。以 此为契机，公司同步强化了生产保障体系，确保能稳定满足集采带来的增量需求。市场营销策略方面， 公司持续深化区域市场战略，通过精细化管理和精准营销策略，不断拓宽销售网络。公司全年营业收入 呈现稳健增长态势，进一步巩固了公司在细分市场的领先地位。 ...

Group 1 - The core viewpoint of the news is that Aojing Medical has seen a stock price increase of 5.15%, reaching 24.50 yuan per share, with a trading volume of 1.11 billion yuan and a turnover rate of 3.44%, resulting in a total market capitalization of 33.57 billion yuan [1] - Aojing Medical, established on December 22, 2004, and listed on May 21, 2021, focuses on the research, production, and sales of high-end biomedical materials and related medical devices [1] - The main revenue composition of Aojing Medical includes: 骼金 74.91%, 颅瑞 16.35%, 齿贝 4.15%, 口腔种植体 2.70%, and other products 1.87% [1] Group 2 - From the perspective of Aojing Medical's top ten circulating shareholders, a fund under Rongtong Fund has entered the top ten shareholders, holding 2.4 million shares, which accounts for 1.75% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) has achieved a year-to-date return of 11.06%, ranking 1397 out of 8861 in its category, and a one-year return of 29.24%, ranking 4302 out of 8126 [2] - The fund manager of Rongtong Health Industry Flexible Allocation Mixed A/B is Wan Minyuan, who has a total fund asset scale of 4.763 billion yuan and has achieved a best fund return of 151.58% during his tenure [3]

股本股东变化 股东增减持 截至2026年1月23日收盘，奥精医疗（688613）报收于24.28元，较上周的23.09元上涨5.15%。本周，奥 精医疗1月23日盘中最高价报24.59元。1月20日盘中最低价报22.85元。奥精医疗当前最新总市值33.27亿 元，在医疗器械板块市值排名108/127，在两市A股市值排名4522/5182。 本周关注点 奥精医疗科技股份有限公司持股5%以上股东北京奇伦天佑创业投资有限公司减持股份计划实施完毕。 减持前奇伦天佑持有公司8,468,000股，占总股本6.18%。自2025年9月24日披露减持计划后，奇伦天佑 于2025年10月23日至2026年1月19日期间通过集中竞价方式累计减持1,355,515股，占公司总股本1%，减 持价格区间为21.00至23.85元/股，减持总金额30,672,196.73元。减持完成后，奇伦天佑持股数量为 7,112,485股，持股比例降至5.19%。本次减持计划已按期完成，未通过大宗交易减持，未提前终止。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 1月 ...